Artificial intelligence is reshaping how antibody discovery programs move from target validation to clinical candidate, replacing sequential trial-and-error with predictive sequence design and early developability triage. For developers evaluating antibody discovery partners, understanding where AI genuinely changes outcomes versus where it remains a marketing claim is critical to setting realistic program timelines and risk expectations.
The questions below address how Nona Biosciences applies AI across the discovery workflow, from lead generation through preclinical development.
What does it mean for AI to be integrated into antibody discovery rather than just used as a supplementary tool?
End-to-end AI integration means AI models participate in decision-making at every stage of the discovery workflow, not just as a post-hoc filter applied to a shortlist of candidates. Nona Biosciences embeds AI from target validation through antibody engineering and CMC, using models to expand sequence diversity and determine which candidates advance to wet lab validation rather than simply scoring molecules that scientists have already selected by other means.
This differs from how many CROs describe “using AI,” where AI functions as a single screening step layered onto an otherwise conventional workflow rather than in parallel to diversify sequences. Nona also operates a data flywheel that actively generates, collects, and curates data to fine-tune proprietary AI models, producing progressively better molecules across iterative discovery cycles. Nona’s Hu-mAtrIx™ (Nona’s AI platform for antibody lead selection and developability optimization) reflects this integrated approach, guiding the incorporation of developability-optimized sequences rather than filtering candidates after the fact.
At what point in a discovery program does AI developability scoring make the biggest difference?
Early lead triage is where AI developability scoring delivers the most value, because this is the stage where scientists must choose a diverse subset of binders to advance to synthesis and testing. Selecting the wrong subset at this point locks in downstream risk that becomes expensive to correct later. AI-based developability scoring identifies molecules with poor folding, aggregation propensity, or other manufacturability risks before they consume synthesis and assay resources, allowing programs to advance a set of candidates with no known developability liabilities rather than a set selected purely on binding affinity.
Can AI-based developability screening actually prevent late-stage failures that traditional screening misses?
Traditional developability screening is a funneled process that assesses manufacturability attributes step by step, which means potent candidates with hidden defects, such as poor folding or aggregation, often survive early stages only to fail later when yield problems surface. This sequential structure is a known weak point in conventional discovery workflows because expensive downstream failures are frequently traceable to developability issues that could have been flagged earlier. AI-based developability assessment identifies these defects and risks at the very beginning of a program, allowing them to be avoided rather than discovered after significant investment. This shifts developability from a late-stage checkpoint to an early-stage design constraint, improving the overall success rate of a discovery campaign.
How does high-throughput single B-cell screening compare to bulk NGS sequencing, and how does AI factor into that comparison?
Single B-cell (SBC) screening recovers antibody sequences at a substantially higher positive rate than next-generation sequencing (NGS) applied to bulk B-cell populations. SBC screening achieves a greater than 70% positive rate for recombinant antibodies, compared to generally less than 10% for NGS-derived sequences, even though SBC retrieves fewer total sequences than NGS. Despite the lower sequence count, SBC still covers the majority of sequence diversity captured by NGS and can identify unique clusters that NGS misses entirely. This recovery advantage matters because it directly reduces the number of candidates that must be screened downstream to find viable leads, and Nona’s Beacon® (single B-cell screening instrument used for high-recovery HCAb isolation) platform is built around this efficiency gain.
|
Metric |
Single B-Cell Screening |
Bulk NGS Sequencing |
|---|---|---|
|
Positive rate for recombinant antibodies |
>70% |
Generally <10% |
|
Sequence diversity coverage |
Covers majority of NGS diversity |
Broader raw sequence output |
|
Unique cluster detection |
Identifies clusters NGS misses |
Higher raw volume, lower specificity |
|
Downstream screening burden |
Lower |
Higher |
Where does AI still fall short in antibody discovery, and where is human judgment still required?
Data scarcity remains the central limiting factor for AI in antibody discovery today. Novel drug development is a high-risk process that requires human scientists to weigh multi-dimensional information, including target biology, experimental reality, and the competitive landscape, not just trade-offs among candidate antibodies. AI models are trained on limited and incomplete data from historical programs, which makes it difficult for them to generalize to novel targets or new therapeutic modalities. This gap explains why AI in antibody discovery is still described industry-wide as being in an early evaluation and optimization phase, with its most significant market impact expected to materialize over the next two to five years rather than having already arrived.
Is AI-driven antibody discovery the same across all providers, or does the underlying data matter?
The quality of AI-driven discovery depends heavily on the proprietary data used to train and validate the models, not just on the existence of an AI layer in the workflow. There is a documented gap between marketing claims about AI in antibody discovery and the actual criteria drug developers use to evaluate candidates, and successful large-scale applications remain limited to organizations with substantial proprietary datasets. Nona’s approach is grounded in a proprietary data flywheel built from its own discovery programs, which trains its proprietary models.
This distinction matters for buyers because AI claims without a demonstrated data foundation behind them are difficult to verify and even harder to translate into program-level outcomes.
How does AI-driven lead optimization fit alongside HCAb-based discovery approaches?
Fully human heavy-chain-only antibodies (HCAbs) provide a naturally compact, single-domain format that pairs well with AI-driven optimization because it reduces the sequence complexity AI models must evaluate compared to conventional two-heavy, two-light chain antibodies. Nona Biosciences’ Hu-mAtrIx™ AI platform integrated in discovery extends this further by guiding the incorporation of developability-optimized sequences directly into HCAb-derived single domains generated through Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies).
This differs from traditional humanization approaches, which must engineer non-human sequences to reduce immunogenicity after the fact, introducing residual risk that AI models then have to account for rather than avoid at the source. Fully human HCAb sequences generated through natural in vivo immune selection give AI developability models a cleaner starting point because there is no residual non-human sequence liability to score around.
What is the realistic timeline impact of AI integration on a program moving from antibody identification to IND filing?
Integrated, parallel discovery workflows that embed AI and developability assessment from the outset typically run 12 to 18 months from antibody identification to IND filing under Nona’s Idea toward IND (I-to-I®) (Nona’s integrated end-to-end service pathway from ideation through IND filing) framework. Most timeline losses in conventional programs come from sequential execution, late alignment between preclinical CMC and developability data, poor species planning for toxicology studies, and non-GLP data that turns out not to be IND-ready, forcing rework. AI-driven early developability triage directly addresses one of these failure points by flagging manufacturability risk before candidates advance, reducing the likelihood of late-stage rework tied to aggregation, chemical stability, or viscosity problems discovered too late in the process.
Programs that enter mid-stream without this early profiling most commonly arrive with incomplete assessment of aggregation propensity, deamidation or oxidation hotspots in CDRs, and freeze-thaw robustness, all of which AI-integrated screening is designed to catch earlier.
Does AI replace the need for high-quality antibody engineering and screening infrastructure?
No, AI performs best as a layer on top of high-recovery screening infrastructure rather than as a replacement for it. AI models generate and prioritize sequence variants, but they depend on high-quality input data from screening platforms to make meaningful predictions, which is why Nona pairs its Hu-mAtrIx™ AI platform with Beacon® single B-cell screening and Harbour Mice® fully human antibody generation rather than deploying AI as a standalone service. Antibody engineering capability, developability assessment, and functional screening remain necessary complements to AI-driven sequence design, particularly for complex modalities like bispecifics and T-cell engagers where structural constraints go beyond what sequence-level prediction alone can resolve.
Developers evaluating discovery partners should ask specifically what proprietary data trains a provider’s AI models and where in the workflow AI actually influences decisions, rather than accepting “AI-powered” as a standalone claim. Partnering with Nona provides access to an AI-integrated discovery workflow built on a data flywheel that continues to improve with each new program.
-
Kohler G., Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 1975. Link
-
Muyldermans S., Nanobodies: natural single-domain antibodies, Annual Review of Biochemistry, 2013. Link
-
Hamers-Casterman C. et al., Naturally occurring antibodies devoid of light chains, Nature, 1993. Link
-
Bailly M. et al., Predicting antibody developability profiles through early stage discovery screening, mAbs, 2020. Link
-
Jain T. et al., Biophysical properties of the clinical-stage antibody landscape, PNAS, 2017. Link
-
Wang B. et al., Machine learning for antibody developability prediction, Nature Reviews Drug Discovery, 2023. Link
-
DeKosky B.J. et al., High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire, Nature Biotechnology, 2013. Link
-
Kaplon H., Reichert J.M., Antibodies to watch, mAbs, 2024. Link
